PM 3023
Alternative Names: PM-3023Latest Information Update: 11 Apr 2022
At a glance
- Originator Biotheus
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 11 Apr 2022 PM 3023 is available for licensing as of 11 Apr 2022. https://www.biotheus.com/Business_Partnership.html
- 05 Apr 2022 Phase-I clinical trials in Cancer (Parenteral) (Biotheus pipeline, April 2022)